Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295880 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL295878 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL2234429 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL293294 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL2234435 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL293293 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL187910 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL661763 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL490446 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL8420441 | 0.82 | KMT2A (0.45) | SMN1; SMN2CA14CA12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2189442-A1 | Process and intermediates for the preparation of aliskiren | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2010-05-26 | — | — | EP | disclosed |
| WO-2008155338-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | CYP1B1, CYP3A7, CYP2F1 | SMN1; SMN2 2689/4885CA14 999/4885CA12 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.